SCHEMBL5536090

SCHEMBL5536090

[c]1ccccc1N1CCC(Oc2ccccc2)C(Oc2ccccc2)C1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSV O60911 3/20 0.49
CTSL P07711 3/20 0.49
CTSB P07858 3/20 0.49
CTSS P25774 3/20 0.49
CTSK P43235 3/20 0.49
CTSC P53634 3/20 0.49
CTSF Q9UBX1 2/20 0.49
CTSH P09668 1/20 0.49
SLC6A2 P23975 2/20 0.33
SLC6A3 Q01959 2/20 0.33
HRH1 P35367 1/20 0.33
FFAR4 Q5NUL3 4/20 0.33
DRD2 P14416 4/20 0.33
DRD4 P21917 4/20 0.33
DRD3 P35462 3/20 0.33
CARM1 Q86X55 1/20 0.32
PRMT6 Q96LA8 1/20 0.32
SLC6A4 P31645 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539182 0.86 CTSV (0.43) CTSVCTSLCTSBCTSSCTSK
SCHEMBL5536838 0.81 HRH1 (0.46) CTSVCTSLCTSBCTSSCTSK
SCHEMBL5536098 0.79 CTSV (0.49) CTSVCTSLCTSBCTSSCTSK
SCHEMBL2094671 0.75 CTSV (0.37) CTSVCTSLCTSBCTSSCTSK
SCHEMBL1450474 0.72 ALDH1A1 (0.39)
SCHEMBL433832 0.72 ALDH1A1 (0.39)
SCHEMBL8457618 0.72 HRH4 (0.40)
SCHEMBL5543469 0.71 EPHX2 (0.44) CARM1PRMT6
SCHEMBL5545404 0.71 EPHX2 (0.44) SLC6A2SLC6A3SLC6A4
SCHEMBL5547830 0.71 MMP13 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CTSV 4638/4885CTSL 4249/4885CTSB 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.